Central Connecticut Dermatology — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$12,319	12
2024	Research	$933	1
2023	Research	$46,355	3
2022	Research	$132,052	9
2021	Research	$234,993	18
2020	Research	$91,863	14

Breakdown

Who paid Research payments · program years 2020–2025

Incyte Corporation $386,500 36 payments
AbbVie, Inc. $125,676 19 payments
Amgen Inc. $6,339 2 payments

Studies the money was for Research payments · program years 2020–2025

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa $314,675 17 payments
M16-833 $89,949 13 payments
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa $47,288 4 payments
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa $35,727 6 payments
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. $12,319 12 payments
A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo $12,217 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.